Swiss National Bank Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Swiss National Bank lifted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 250,700 shares of the company’s stock after purchasing an additional 17,900 shares during the period. Swiss National Bank owned about 0.18% of Denali Therapeutics worth $7,303,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Bayesian Capital Management LP acquired a new stake in Denali Therapeutics during the 1st quarter worth $447,000. Candriam S.C.A. increased its stake in Denali Therapeutics by 62.2% in the second quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock valued at $16,869,000 after purchasing an additional 278,621 shares during the period. Integral Health Asset Management LLC acquired a new position in Denali Therapeutics in the second quarter valued at $7,546,000. Vanguard Group Inc. increased its stake in Denali Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company’s stock valued at $225,069,000 after purchasing an additional 133,810 shares during the period. Finally, Rhumbline Advisers increased its stake in Denali Therapeutics by 13.3% in the second quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after purchasing an additional 22,900 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares of the company’s stock, valued at $6,529,495.83. The trade was a 14.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock valued at $2,474,440 over the last quarter. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $24.50 on Tuesday. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33. The company has a market capitalization of $3.53 billion, a PE ratio of -8.88 and a beta of 1.40. The firm’s 50-day moving average is $27.88 and its two-hundred day moving average is $24.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm earned ($0.72) EPS. On average, analysts forecast that Denali Therapeutics Inc. will post -2.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Citigroup lifted their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Jefferies Financial Group lifted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research note on Thursday, November 7th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.